The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma

Opinion
Video

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, provide an overview of the current treatment landscape in relapsed/refractory multiple myeloma.

CN_BTL_MM_Seg01_Landscape
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question:

      • What is the current treatment landscape for relapsed/refractory multiple myeloma (R/R MM)?
      Recent Videos
      Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
      Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
      Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
      Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
      From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
      From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
      From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
      From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
      Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
      Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
      CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
      CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
      3 experts in this video
      Key Takeaways and Future in Advanced Gastric Cancer Treatment
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      3 experts in this video
      Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
      3 experts in this video
      Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
      Related Content
      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma

      Russ Conroy
      March 23rd 2025
      Article

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Pomalidomide Combo Sustains Improved Outcomes in Pretreated R/R Myeloma

      Russ Conroy
      March 19th 2025
      Article

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

      ONCOLOGY Staff
      March 9th 2025
      Article

      A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.

      Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.

      Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies

      Roman Fabbricatore
      March 7th 2025
      Article

      Lenalidomide capsules and dasatinib tablets have received FDA approval through an abbreviated new drug application for various hematologic malignancies.